Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Markovic

Showing results (341-350 of 368) with videos related to

Pageof 37
Sort By:
Mayo Clinic Proceedings|April 10, 2007
Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatmentSvetomir N Markovic, Lori A Erickson, Ravi D Rao, et al.
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.
Plos One|March 21, 2020
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutationsThomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, et al.
Mayo Clinic Proceedings|March 14, 2007
Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosisSvetomir N Markovic, Lori A Erickson, Ravi D Rao, et al.
Cancer|September 12, 2013
Pediatric melanoma: analysis of an international registryBruce J Averbook, Sandra J Lee, Keith A Delman, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|February 17, 2009
Metastatic malignant melanomaS N Markovic, L A Erickson, T J Flotte, et al.
International Journal of Cancer|March 19, 2021
Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinomaLionel A Kankeu Fonkoua, Sakti Chakrabarti, Mohamad B Sonbol, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanomaTina J Hieken, David Zahrieh, Thomas J Flotte, et al.
American Journal of Clinical Oncology|April 9, 2013
Rare presentations of primary melanoma and special populations: a systematic reviewLisa A Kottschade, Travis E Grotz, Roxana S Dronca, et al.
Journal for Immunotherapy of Cancer|April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trialMatthew S Block, Garth D Nelson, Jun Chen, et al.
Pageof 37

Showing results (341-350 of 368) with videos related to

Sort By:
Pageof 37
Mayo Clinic Proceedings|April 10, 2007
Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatmentSvetomir N Markovic, Lori A Erickson, Ravi D Rao, et al.
American Journal of Hematology|February 18, 2017
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphomaN Nora Bennani, Betsy R LaPlant, Stephen M Ansell, et al.
Plos One|March 21, 2020
Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutationsThomas T DeLeon, Daniel R Almquist, Benjamin R Kipp, et al.
Mayo Clinic Proceedings|March 14, 2007
Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosisSvetomir N Markovic, Lori A Erickson, Ravi D Rao, et al.
Cancer|September 12, 2013
Pediatric melanoma: analysis of an international registryBruce J Averbook, Sandra J Lee, Keith A Delman, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|February 17, 2009
Metastatic malignant melanomaS N Markovic, L A Erickson, T J Flotte, et al.
International Journal of Cancer|March 19, 2021
Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinomaLionel A Kankeu Fonkoua, Sakti Chakrabarti, Mohamad B Sonbol, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanomaTina J Hieken, David Zahrieh, Thomas J Flotte, et al.
American Journal of Clinical Oncology|April 9, 2013
Rare presentations of primary melanoma and special populations: a systematic reviewLisa A Kottschade, Travis E Grotz, Roxana S Dronca, et al.
Journal for Immunotherapy of Cancer|April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trialMatthew S Block, Garth D Nelson, Jun Chen, et al.
Pageof 37